A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

Trial Profile

A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Feb 2018 Planned End Date changed from 8 Nov 2018 to 10 Sep 2018.
    • 02 Feb 2018 Planned primary completion date changed from 8 Nov 2018 to 10 Sep 2018.
    • 02 Feb 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top